Florbetapir PET
In a review, the German Institute for Quality and Efficiency in Health Care (the institute that investigates the benefits and...
Results of a two-year Phase III study of Tradjenta (linagliptin), from Boehringer and Eli Lilly, show significant reductions in blood...
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with Tradjenta...
Boehringer Ingelheim and Eli Lilly and Company announced detailed findings from the CAROLINA trial demonstrating that Tradjenta (linagliptin) did not...
Boehringer Ingelheim and Eli Lilly and Company have initiated a study of the efficacy and safety of Tradjenta ( linagliptin)...
Results from a new pooled meta-analysis of Phase III data for Tradjenta (linagliptin), from Boehringer/Eli Lilly, in patients with Type...
Results from the MARLINA-T2D trial demonstrated that Tradjenta (linagliptin), from Boehringer and Eli Lilly, reduced blood sugar in adults with...
Results from two post-hoc, pooled analyses of trials examining the safety of Tradjenta (linagliptin), from Boehringer and Eli Lilly, in...